In vitro studies of ferritin iron release and neurotoxicity

Journal of Neurochemistry

Volumn 70, Issue 6, 1998, Pages 2492-2499

  Double, K L ^a   Maywald, M ^a   Schmittel, M ^a   Riederer, P ^a   Gerlach, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

1,2,4 Trihydroxybenzene; 6 Hydroxydopamine; Dopamine; Ferritin; Iron; Neurotoxicity

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM IODIDE; 1 TRICHLOROMETHYL 1,2,3,4 TETRAHYDRO BETA CARBOLINE; 1,2,4 BENZENETRIOL; DOPAMINE; FERRITIN; FERROZINE; HYDROQUINONE; OXIDOPAMINE; RESORCINOL; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CHEMICAL STRUCTURE; DEGENERATIVE DISEASE; IRON METABOLISM; LIPID PEROXIDATION; NEUROTOXICITY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

ANIMALIA;

EID: 0031778102     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70062492.x     Document Type: Article

References (38)

1. Akiyama M. and Ikeda T. (1995) Design and synthesis of artificial siderophores - lysine-based triscatecholate ligands as a model for enterobactin. Chem. Lett. 9, 849-850.
2. Ben-Shachar D. and Youdim M. B. H. (1991) Intranigral iron injection induces behavioural and biochemical "parkinsonism" in rats. J. Neurochem. 57, 2133-2135.
3. Ben-Shachar D., Eshel G., Finberg J. P. M., and Youdim M. B. H. (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441-1444.
4. Boyer R. F., Clark H. M., and LaRoche A. P. (1988) Reduction and release of ferritin iron by plant phenolics. J. Inorg. Biochem. 32, 171-181.
5. Bradford M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
6. Brede O., Orthner H., Zubarev V., and Hermann R. (1996) Radical cations of sterically hindered phenols as intermediates in radiation-induced electron transfer processes. J. Phys. Chem. 100, 7097-7105.
7. Bringmann G., God R., Feineis D., Weseman W., Riederer P., Rausch W.-D., Reichman H., and Sontag K.-H. (1995) The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline (TaClo), a new toxin for dopaminergic neurons. J. Neural Transm. Suppl. 46, 235-244.
8. Cohen G. and Heikkila A. J. (1974) Degeneration of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 249, 2447-2452.
9. Cohen G., Heikkila R. E., Allis B., Cabbat F., Dembiec D., MacNamee D., Mytilineou C., and Winston B. (1976) Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. J. Pharmacol. Exp. Ther. 199, 336-352.
10. Dexter D. T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., Lees A. J., Wells F. R., Jenner P., and Marsden C. D. (1990) Decreased ferritin levels in brain of Parkinson's disease. J. Neurochem. 55, 16-20.
11. Dexter D. T., Carayon A., Javoy-Agid F., Agid Y., Wells F. R., Daniel S. E., Lees A. J., Jenner P., and Marsden C. D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
12. Ebersen L. (1992) Outer-sphere electron transfer reactions, rare events in organic chemistry? New J. Chem. 16, 151-156.
13. 2. Biochim. Biophys. Acta 838, 183-190.
14. Gee P. and Davison A. J. (1989) Intermediates in the aerobic autoxidation of 6-hydroxydopamine: relative importance under different reaction conditions. J. Free Radic. Med. 6, 271-284.
15. Gerlach M. and Riederer P. (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. Gen. Sect. 103, 987-1041.
16. Gerlach M., Ben-Shachar D., Riederer P., and Youdim M. B. H. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63, 793-807.
17. Graham D. G., Tiffany S. M., Bell W. M., and Gutknecht W. F. (1978) Autoxidation versus covalent binding of quinones as the mechanisms of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
18. Hall S., Rulledge J. H., and Schallert T. (1992) MRI brain iron and 6-hydroxydopamine experimental Parkinson's disease. J. Neurol. Sci. 113, 198-208.
19. Halliwell B. (1992) Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623.
20. Harrison P. M. and Arosio P. (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275, 161-203.
21. Heikkila R. and Cohen G. (1971) Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine. Science 112, 1257-1258.
22. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., and Youdim M. B. H. (1990) Brain iron and ferritin in Parkinson's disease and Alzheimer's disease. J. Neural Transm. Park. Dis. Dement. Sect. 2, 327-340.
23. Jellinger K., Linert L., Kienzl E., and Youdim M. B. H. (1995) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. Suppl. 46, 297-314.
24. Koster J. F. and Slee R. G. (1986) Ferritin, a physiological iron donor for microsomal lipid peroxidation. FEBS Lett. 199, 85-88.
25. Linert W., Herlinger E., Jameson R. F., Kienzl E., Jellinger K., and Youdim M. B. H. (1996) Dopamine, 6-hydroxydopamine, iron and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316, 160-168.
26. Lode H. N., Bruchelt G., Rieth A. G., and Niethammer D. (1990) Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions. Free Radic. Res. Commun. 11, 153-158.
27. Mann V. M., Cooper J. M., Daniel S. E., Srai K., Jenner P., Marsden C. D., and Schapira A. H. (1994) Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36, 876-881.
28. Monteiro H. P. and Winterbourn C. C. (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38, 4177-4182.
29. Oestreicher E., Sengstock G. J., Riederer P., Olanow C. W., Dunn A. J., and Arendash G. W. (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660, 8-18.
30. Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G. P., Jellinger K., and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
31. Scarrow R., Ecker D., Ng C., Liu S., and Raymond K. (1991) Iron (III) coordination chemistry of linear dihydroxyserine compounds derived from enterobactin. Inorg. Chern. 30, 900-906.
32. Sengstock G. W., Olanow C. W., Dunn A. J., and Arendash G. W. (1991a) Iron induces degeneration of nigrostriatal neurons. Brain Res. Bull. 28, 645-649.
33. Sengstock G. W., Olanow C. W., Menzies R. A., Dunn A. J., and Arendash G. W. (1991b) Infusion of iron into the rat substantia nigra: nigral pathology and dose dependent loss of dopaminergic markers. J. Neurosci. Res. 34, 67-82.
34. Stookey L. L. (1970) Ferrozine - a new spectrophotometric reagent for iron. Anal. Chem. 42, 779-781.
35. Suh J., Lee S., and Paik H. (1994) An enterobactin analog prepared by cross-linking a preassembled iron (III) complex of a catechol derivative with poly(ethyline imine). Inorg. Chem. 33, 3-4.
36. Uitti R. J., Rajput A. H., Rozdilsky B., Bickis M., Wollin T., and Yuen W. K. (1989) Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can. J. Neurol Sci. 16, 310-314.
37. Wesemann W., Blaschke S., Solbach M., Grote C., Clement H.-W., and Riederer P. (1994) Intranigral injected iron progressively reduces striatal dopamine metabolism. J. Neural Transm. Park. Dis. Dement. Sect. 8, 209-214.
38. Williams R. J. P. (1982) Free manganese(II) and iron(II) cations can act as intracellular cell controls. FEBS Lett. 140, 3-10.